Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update